Take the steps now
to secure your future
to secure your future
LYNCHNOW is a cost-effective, screening tool that rapidly detects mutations that cause Lynch syndrome.
LYNCHNOW is a germline screening tool used to test for Lynch syndrome and other hereditary cancer disorders in patients with colorectal cancer.
This test is designed for colorectal cancer patients with a positive family history of hereditary cancers or a suspicion of Lynch syndrome (e.g. MSI-high or mismatch repair deficiency (dMMR)). We offer two iterations of the test: LYNCHNOW Basic, which screens the Lynch syndrome genes (MLH1, MSH2, MHS6, PMS2, EPCAM), and LYNCHNOWExtended, a comprehensive 32-gene panel that identifies alterations in genes associated with Lynch syndrome and other hereditary disorders related to increased risk for colorectal cancer. Reflex options are available. Both versions of the assay utilize next-generation sequencing and detect single- and multi-nucleotide substitutions and small insertions and deletions in coding regions and exon-intron junctions, as well as large genomic rearrangements of the target genes, providing >20X average coverage at the targeted genomic regions of the tested genes.
The protocol, which is largely accepted throughout the medical field, consists of first screening for DNA mismatch repair (MMR) proteins MLH1, MSH2, MSH6, and PMS2 by way of immunohistochemistry.
The protocol, which is largely accepted throughout the medical field, consists of first screening for DNA mismatch repair (MMR) proteins MLH1, MSH2, MSH6, and PMS2 by way of immunohistochemistry.
LYNCHNOW® Extended Panel 32 analyzed genes
This COMPREHENSIVE GERMLINE PANEL analyzes 88 clinically-relevant genes that are associated with genetic disorders, including most hereditary cancers.
PROSTATENOW is a germline test for people with prostate cancer. This test can be used to predict prognosis among men with localized prostate cancer, predict therapeutic responses for advanced patients, and predict cancer risk among unaffected men.
There is an increased likelihood of a BRCA1 or BRCA2 mutation in patients with certain personal and family history characteristics and various clinical criteria. BRCANOW is a Next-Gen Sequencing (NGS)-based assay using a state-of-the-art platform to detect whether or not a mutation is present.
DIABETESNOW is a unique genetic panel that tests for 16 genes associated with MODY, syndromic, neonatal, and mitochondrial causes of monogenic diabetes. It also includes pan-ancestry type 1 and 2 diabetes polygenic risk scores (PRS) and the probability of type 1 diabetes (GenProb-T1D).
We're here to guide you through the process.
LYNCHNOW® includes genetic counseling to walk you through our process and test results, along with any lifestyle or treatment alternatives depending on your results.
